Keros Financial Statements From 2010 to 2026
| KROS Stock | USD 18.54 1.82 8.94% |
Check Keros Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Keros Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Keros financial statements analysis is a perfect complement when working with Keros Therapeutics Valuation or Volatility modules.
Check out the analysis of Keros Therapeutics Correlation against competitors. Keros Therapeutics Company Return On Asset Analysis
Keros Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Keros Therapeutics Return On Asset | 0.044 |
Most of Keros Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Keros Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Keros Therapeutics has a Return On Asset of 0.044. This is 100.5% lower than that of the Biotechnology sector and 100.19% lower than that of the Health Care industry. The return on asset for all United States stocks is 131.43% lower than that of the firm.
Keros Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Keros Therapeutics's current stock value. Our valuation model uses many indicators to compare Keros Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Keros Therapeutics competition to find correlations between indicators driving Keros Therapeutics's intrinsic value. More Info.Keros Therapeutics is rated fourth overall in return on equity category among its peers. It also is rated fourth overall in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Keros Therapeutics is roughly 2.37 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Keros Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Keros Therapeutics Financial Statements
Keros Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Keros Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Keros Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Keros Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Keros Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 97 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.